Lilly asks migraine patients to 'imagine' in Emgality push by Beth Snyder Bulik Thursday, February 14, 2019 Eli Lilly's new Emgality work is based on research with patients who experience the sometimes debilitating effects of migraine but refuse to give up.
Lartruvo failure, Loxo buy dent Lilly’s 2019 hopes by Arlene Weintraub Wednesday, February 6, 2019 After Eli Lilly lowered its sales and earnings projections, analysts demanded details about new products—including migraine drug Emgality.
Teva migraine drug Ajovy sidelined by another PBM by Eric Sagonowsky Monday, February 4, 2019 UnitedHealthcare's pharmacy benefits outfit OptumRx picked Amgen and Eli Lilly CGRP drugs for its preferred coverage list, handing Teva a setback.
Botox can hold its own in growing migraine field, Allergan says by Eric Sagonowsky Thursday, January 31, 2019 Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.
CVS sidelines Amgen's Aimovig in favor of Teva, Lilly CGRP drugs by Eric Sagonowsky Monday, January 28, 2019 CVS' coverage decision for Amgen's Aimovig marks a setback for the company's launch and a boost for rivals Teva and Eli Lilly.
Cost watchdogs deal Novartis a blow with Aimovig rejection by Angus Liu Thursday, January 10, 2019 England's National Institute for Health and Care Excellence says available clinical data aren't enough to demonstrate Aimovig's cost-effectiveness.
Lilly's Emgality launch paving the way for a pain franchise: exec by Eric Sagonowsky Wednesday, January 9, 2019 Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.
Lilly lays out sunny 2019 forecast driven by growth of new meds by Arlene Weintraub Wednesday, December 19, 2018 Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
Lilly weighs $200M-plus sale of China drug portfolio: report by Arlene Weintraub Friday, November 16, 2018 Eli Lilly may have found one way to raise some quick cash to pour into its portfolio of growth prospects.
Lilly nets 'breakthrough' for CGRP Emgality by Eric Sagonowsky Thursday, November 15, 2018 The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.
